RxDoctor Payments Data

Timothy Kasunic, MD

Hematology & Oncology · Toledo, OHNPI 1013975903

Payments from drug & device makers

$1,026in general payments, 2019–2025

Across 26 payments — averaging $39.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$400
  • Johnson & Johnson$189
  • Tempus AI, Inc$154
  • AstraZeneca$34
  • Takeda Pharmaceuticals U.S.A., Inc.$31
  • Pfizer$27
  • plus $191 from 10 others

What the payments were for

  • Consulting fees$40039%
  • Food & beverage$46545%
  • Education$16016%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,026 in reported general payments places this provider in the 25th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$6,018,803
Medicare patients
809
Services billed
319,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib93$1,412,093
VenclextaVenetoclax100$1,196,182
ImbruvicaIbrutinib40$590,832
ScemblixAsciminib Hydrochloride15$408,806
XtandiEnzalutamide27$381,912
NubeqaDarolutamide27$372,068
TalzennaTalazoparib Tosylate14$248,309
TasignaNilotinib Hcl12$242,721
VerzenioAbemaciclib15$228,916
ErleadaApalutamide14$209,118
Everolimus20$163,279
Abiraterone Acetate120$121,162
PegasysPeginterferon Alfa-2a27$116,771
EliquisApixaban111$84,026
Gefitinib11$60,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Talzenna, Eliquis$27$1,744,429218 claims
AbbVieVenclexta$25$1,196,182100 claims
Astellas Pharma US IncXtandi$20$381,91227 claims
Johnson & JohnsonErleada, Xarelto$189$235,02344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →